Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Drug-drug Interactions of Short-course Treatment of Latent Tuberculosis Infection With High-dose Once-weekly Rifapentine and Isoniazid (3HP) Among Infants, Children and Adolescents Living With HIV Taking Dolutegravir-based Antiretroviral Treatment

NCT05122767 is registered in ClinicalTrials.gov with The Aurum Institute NPC as lead sponsor.

NCT NCT05122767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05122767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Drug-drug Interactions of Short-course Treatment of Latent Tuberculosis Infection With High-dose Once-weekly Rifapentine and Isoniazid (3HP) Among Infants, Children and Adolescents Living With HIV Taking Dolutegravir-based Antiretroviral Treatment
Lead sponsor
The Aurum Institute NPC
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 24, 2023
Completion date
December 31, 2025
Enrollment
92 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, tuberculosis